Radiopharm Theranostics Announces Data From All Thirty Evaluable Patients In Its Phase 2B Trial Of RAD101 In Participants With Suspected Recurrence Of Brain Metastases After Radiotherapy; RAD101 PET Demonstrated 93% Concordance With MRI Across All...

Radiopharm Theranostics Limited Sponsored ADR

RADX

0.00

14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective). Specificity data will be available in Q4 2026.

The Company plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026

The imaging Brain Metastases total addressable market is ~$600+m for which there is no currently approved PET product

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.